Gene Young Im

Gene Young Im

Auto-generated profile, based on publicly available information

Gene Young Im

Division of Digestive and Liver Diseases, Center for Liver Disease and Transplantation Columbia University New York City New York USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2019 in Hepatology
Verified
Journal Article
Open access
PDF file
DCDavid W. Crabb
David W. Crabb
GIGene Y. Im
Gene Y. Im
GSGyongyi Szabo
Gyongyi Szabo
JMJessica L. Mellinger
Jessica L. Mellinger
MLMichael R. Lucey
Michael R. Lucey
Click on the article title to read more.

1 August 2018 in Gastroenterology
Verified
Journal Article
Open access
PDF file
BLBrian P. Lee
Brian P. Lee
NMNeil Mehta MD
Neil Mehta MD
LPLaura Platt
Laura Platt
AGAhmet Gurakar
Ahmet Gurakar
JRJohn P. Rice
John P. Rice
NTNorah A. Terrault
Norah A. Terrault
Background & Aims The American Consortium of Early Liver Transplantation for Alcoholic Hepatitis comprises 12 centers from 8 United Network for Organ Sharing regions studying early liver transplantation (LT) (without mandated period of sobriety) for patients with severe alcoholic hepatitis (AH). We analyzed the outcomes of these patients. Methods We performed a retrospective study of consecutive patients with a diagnosis of severe AH and no prior diagnosis of liver disease or episodes of AH, who underwent LT before 6 months of abstinence from 2006 through 2017 at 12 centers. We collected data on baseline characteristics, psychosocial profiles, level of alcohol consumption before LT, disease course and treatment, and outcomes of LT. The interval of alcohol abstinence was defined as the time between last drink and the date of LT. The primary outcomes were survival and alcohol use after LT, defined as slip or sustained. Results Among 147 patients with AH who received liver transplants, the median duration of abstinence before LT was 55 days; 54% received corticosteroids for AH and the patients had a median Lille score of 0.82 and a median Sodium Model for End-Stage Liver Disease score of 39. Cumulative patient survival percentages after LT were 94% at 1 year (95% confidence interval [CI], 89%–97%) and 84% at 3 years (95% CI, 75%–90%). Following hospital discharge after LT, 72% were abstinent, 18% had slips, and 11% had sustained alcohol use. The cumulative incidence of any alcohol use was 25% at 1 year (95% CI, 18%–34%) and 34% at 3 years (95% CI, 25%–44%) after LT. The cumulative incidence of sustained alcohol use was 10% at 1 year (95% CI, 6%–18%) and 17% at 3 years (95% CI, 10%–27%) after LT. In multivariable analysis, only younger age was associated with alcohol following LT (P = .01). Sustained alcohol use after LT was associated with increased risk of death (hazard ratio, 4.59; P = .01). Conclusions In a retrospective analysis of 147 patients who underwent early LT (before 6 months of abstinence) for severe AH, we found that most patients survive for 1 year (94%) and 3 years (84%), similar to patients receiving liver transplants for other indications. Sustained alcohol use after LT was infrequent but associated with increased mortality. Our findings support the selective use of LT as a treatment for severe AH. Prospective studies are needed to optimize selection criteria, management of patients after LT, and long-term outcomes.

1 March 2016 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
GIG. Y. Im
G. Y. Im
LKL. Kim-Schluger
L. Kim-Schluger
ASA. Shenoy
A. Shenoy
ESE. Schubert
E. Schubert
AGA. Goel
A. Goel
TST. D. Schiano
T. D. Schiano
Early liver transplantation (LT) in European centers reportedly improved survival in patients with severe alcoholic hepatitis (AH) not responding to medical therapy. Our aim was to determine if a strategy of early LT for severe AH could be applied successfully in the United States. We reviewed 111 patients with severe AH at our center from January 2012 to January 2015. The primary end point was mortality at 6 months or early LT, with a secondary end point of alcohol relapse after LT. Survival was compared between those receiving early LT and matched patients who did not. Using a process similar to the European trial, 94 patients with severe AH not responding to medical therapy were evaluated for early LT. Overall, 9 (9.6%) candidates with favorable psychosocial profiles underwent early LT, comprising 3% of all adult LT during the study period. The 6-month survival rate was higher among those receiving early LT compared with matched controls (89% vs 11%, p<0.001). Eight recipients are alive at a median of 735 days with 1 alcohol relapse. Early LT for severe AH can achieve excellent clinical outcomes with low impact on the donor pool and low rates of alcohol relapse in highly selected patients in the United States.


18 December 2018 in Hepatology
Verified
Journal Article
Closed access
PDF file
BLBrian P. Lee
Brian P. Lee
EVEric Vittinghoff
Eric Vittinghoff
CHChristine Hsu
Christine Hsu
HHHyosun Han
Hyosun Han
George TherapondosGeorge Therapondos
George Therapondos
NTNorah A. Terrault
Norah A. Terrault

19 November 2019 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
SASumeet K. Asrani
Sumeet K. Asrani
JTJames Trotter
James Trotter
JLJack Lake
Jack Lake
AAAijaz Ahmed
Aijaz Ahmed
ABAnthony Bonagura
Anthony Bonagura
GKGoran Klintmalm
Goran Klintmalm